Sen-Jam Pharmaceutical

Recent Finacing

Equity

Recent Raise

Undisclosed

Sen-Jam Pharmaceutical develops anti-inflammatory and metabolic therapies using its PAIR platform, advancing lead candidate SJP-001 into an Australian Phase 2 clinical trial managed by CRO Novotech.

Founded 2014

New York, United States

1-10

Private

sen-jam.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Pharmaceutical

Recent Investors

5

Financials

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at Sen-Jam Pharmaceutical.